Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Asset Writedowns and Impairment (2020 - 2025)

Historic Asset Writedowns and Impairment for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to $132000.0.

  • Cytek Biosciences' Asset Writedowns and Impairment fell 6129.03% to $132000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $735000.0, marking a year-over-year decrease of 6411.13%. This contributed to the annual value of $1.6 million for FY2024, which is 1212.53% up from last year.
  • As of Q3 2025, Cytek Biosciences' Asset Writedowns and Impairment stood at $132000.0, which was down 6129.03% from $21000.0 recorded in Q2 2025.
  • In the past 5 years, Cytek Biosciences' Asset Writedowns and Impairment ranged from a high of $912000.0 in Q1 2024 and a low of -$58000.0 during Q2 2021
  • In the last 5 years, Cytek Biosciences' Asset Writedowns and Impairment had a median value of $202000.0 in 2023 and averaged $253947.4.
  • In the last 5 years, Cytek Biosciences' Asset Writedowns and Impairment skyrocketed by 58648.65% in 2023 and then tumbled by 8320.0% in 2025.
  • Over the past 5 years, Cytek Biosciences' Asset Writedowns and Impairment (Quarter) stood at $155000.0 in 2021, then surged by 89.68% to $294000.0 in 2022, then surged by 127.89% to $670000.0 in 2023, then tumbled by 60.0% to $268000.0 in 2024, then plummeted by 50.75% to $132000.0 in 2025.
  • Its last three reported values are $132000.0 in Q3 2025, $21000.0 for Q2 2025, and $314000.0 during Q1 2025.